nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—HRH1—atherosclerosis	0.847	1	CbGaD
Doxylamine—Loss of libido—Lovastatin—atherosclerosis	0.00325	0.0229	CcSEcCtD
Doxylamine—Loss of libido—Simvastatin—atherosclerosis	0.00304	0.0214	CcSEcCtD
Doxylamine—Loss of libido—Pravastatin—atherosclerosis	0.00275	0.0193	CcSEcCtD
Doxylamine—Liver disorder—Ezetimibe—atherosclerosis	0.00216	0.0152	CcSEcCtD
Doxylamine—Liver disorder—Simvastatin—atherosclerosis	0.00206	0.0145	CcSEcCtD
Doxylamine—Redness—Niacin—atherosclerosis	0.00191	0.0134	CcSEcCtD
Doxylamine—Liver disorder—Pravastatin—atherosclerosis	0.00186	0.0131	CcSEcCtD
Doxylamine—Nightmare—Rosuvastatin—atherosclerosis	0.00171	0.012	CcSEcCtD
Doxylamine—Bone disorder—Ezetimibe—atherosclerosis	0.00163	0.0115	CcSEcCtD
Doxylamine—Bone disorder—Niacin—atherosclerosis	0.00143	0.01	CcSEcCtD
Doxylamine—Nightmare—Simvastatin—atherosclerosis	0.00135	0.00954	CcSEcCtD
Doxylamine—Nightmare—Pravastatin—atherosclerosis	0.00122	0.00862	CcSEcCtD
Doxylamine—Haemolytic anaemia—Lovastatin—atherosclerosis	0.00121	0.00849	CcSEcCtD
Doxylamine—Breast disorder—Rosuvastatin—atherosclerosis	0.00116	0.00817	CcSEcCtD
Doxylamine—Haemolytic anaemia—Simvastatin—atherosclerosis	0.00113	0.00794	CcSEcCtD
Doxylamine—Pancreatitis—Rosuvastatin—atherosclerosis	0.00109	0.00766	CcSEcCtD
Doxylamine—Polyuria—Niacin—atherosclerosis	0.00106	0.0075	CcSEcCtD
Doxylamine—Haemolytic anaemia—Pravastatin—atherosclerosis	0.00102	0.00718	CcSEcCtD
Doxylamine—Depression—Rosuvastatin—atherosclerosis	0.000987	0.00695	CcSEcCtD
Doxylamine—Cramp muscle—Lovastatin—atherosclerosis	0.00098	0.0069	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00098	0.0069	CcSEcCtD
Doxylamine—Breast disorder—Ezetimibe—atherosclerosis	0.000965	0.00679	CcSEcCtD
Doxylamine—Cramp muscle—Ezetimibe—atherosclerosis	0.000962	0.00677	CcSEcCtD
Doxylamine—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000955	0.00672	CcSEcCtD
Doxylamine—Pancreatitis—Lovastatin—atherosclerosis	0.000923	0.0065	CcSEcCtD
Doxylamine—Diplopia—Pravastatin—atherosclerosis	0.000921	0.00648	CcSEcCtD
Doxylamine—Cramp muscle—Simvastatin—atherosclerosis	0.000917	0.00646	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.000917	0.00646	CcSEcCtD
Doxylamine—Affect lability—Pravastatin—atherosclerosis	0.000906	0.00638	CcSEcCtD
Doxylamine—Pancreatitis—Ezetimibe—atherosclerosis	0.000905	0.00637	CcSEcCtD
Doxylamine—Abdominal discomfort—Lovastatin—atherosclerosis	0.000902	0.00635	CcSEcCtD
Doxylamine—Urinary retention—Niacin—atherosclerosis	0.000889	0.00626	CcSEcCtD
Doxylamine—Hepatitis—Rosuvastatin—atherosclerosis	0.000889	0.00626	CcSEcCtD
Doxylamine—Mood swings—Pravastatin—atherosclerosis	0.000872	0.00614	CcSEcCtD
Doxylamine—Pancreatitis—Simvastatin—atherosclerosis	0.000863	0.00608	CcSEcCtD
Doxylamine—Orthostatic hypotension—Niacin—atherosclerosis	0.000854	0.00601	CcSEcCtD
Doxylamine—Abdominal discomfort—Simvastatin—atherosclerosis	0.000844	0.00594	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000832	0.00586	CcSEcCtD
Doxylamine—Cramp muscle—Pravastatin—atherosclerosis	0.000829	0.00584	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000829	0.00584	CcSEcCtD
Doxylamine—Nasopharyngitis—Pravastatin—atherosclerosis	0.000823	0.0058	CcSEcCtD
Doxylamine—Depression—Simvastatin—atherosclerosis	0.000782	0.00551	CcSEcCtD
Doxylamine—Pancreatitis—Pravastatin—atherosclerosis	0.00078	0.00549	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000778	0.00548	CcSEcCtD
Doxylamine—Sweating increased—Pravastatin—atherosclerosis	0.000775	0.00546	CcSEcCtD
Doxylamine—Hepatitis—Lovastatin—atherosclerosis	0.000753	0.0053	CcSEcCtD
Doxylamine—Hepatitis—Ezetimibe—atherosclerosis	0.000739	0.0052	CcSEcCtD
Doxylamine—Erythema multiforme—Lovastatin—atherosclerosis	0.000712	0.00501	CcSEcCtD
Doxylamine—Depression—Pravastatin—atherosclerosis	0.000707	0.00498	CcSEcCtD
Doxylamine—Angioedema—Rosuvastatin—atherosclerosis	0.000707	0.00498	CcSEcCtD
Doxylamine—Hepatitis—Simvastatin—atherosclerosis	0.000704	0.00496	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000703	0.00495	CcSEcCtD
Doxylamine—Flushing—Lovastatin—atherosclerosis	0.000699	0.00492	CcSEcCtD
Doxylamine—Erythema multiforme—Ezetimibe—atherosclerosis	0.000698	0.00492	CcSEcCtD
Doxylamine—Sweating—Niacin—atherosclerosis	0.000691	0.00486	CcSEcCtD
Doxylamine—Flushing—Ezetimibe—atherosclerosis	0.000686	0.00483	CcSEcCtD
Doxylamine—Chloropyramine—HRH1—atherosclerosis	0.000677	0.0894	CrCbGaD
Doxylamine—Immune system disorder—Ezetimibe—atherosclerosis	0.000667	0.0047	CcSEcCtD
Doxylamine—Erythema multiforme—Simvastatin—atherosclerosis	0.000666	0.00469	CcSEcCtD
Doxylamine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000666	0.00469	CcSEcCtD
Doxylamine—Flushing—Simvastatin—atherosclerosis	0.000654	0.0046	CcSEcCtD
Doxylamine—Hepatitis—Niacin—atherosclerosis	0.000647	0.00455	CcSEcCtD
Doxylamine—Dexbrompheniramine—HRH1—atherosclerosis	0.000646	0.0853	CrCbGaD
Doxylamine—Erythema—Ezetimibe—atherosclerosis	0.000643	0.00453	CcSEcCtD
Doxylamine—Hepatitis—Pravastatin—atherosclerosis	0.000637	0.00448	CcSEcCtD
Doxylamine—Confusional state—Rosuvastatin—atherosclerosis	0.000637	0.00448	CcSEcCtD
Doxylamine—Pheniramine—HRH1—atherosclerosis	0.000632	0.0835	CrCbGaD
Doxylamine—Muscle spasms—Lovastatin—atherosclerosis	0.00063	0.00444	CcSEcCtD
Doxylamine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000619	0.00436	CcSEcCtD
Doxylamine—Muscle spasms—Ezetimibe—atherosclerosis	0.000618	0.00435	CcSEcCtD
Doxylamine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000618	0.00435	CcSEcCtD
Doxylamine—Tremor—Lovastatin—atherosclerosis	0.000614	0.00432	CcSEcCtD
Doxylamine—Erythema—Simvastatin—atherosclerosis	0.000613	0.00432	CcSEcCtD
Doxylamine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000608	0.00428	CcSEcCtD
Doxylamine—Clemastine—HRH1—atherosclerosis	0.000607	0.0802	CrCbGaD
Doxylamine—Eye disorder—Niacin—atherosclerosis	0.000605	0.00426	CcSEcCtD
Doxylamine—Erythema multiforme—Pravastatin—atherosclerosis	0.000602	0.00424	CcSEcCtD
Doxylamine—Flushing—Niacin—atherosclerosis	0.0006	0.00423	CcSEcCtD
Doxylamine—Angioedema—Lovastatin—atherosclerosis	0.000599	0.00422	CcSEcCtD
Doxylamine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000597	0.0042	CcSEcCtD
Doxylamine—Malaise—Lovastatin—atherosclerosis	0.000591	0.00416	CcSEcCtD
Doxylamine—Flushing—Pravastatin—atherosclerosis	0.000591	0.00416	CcSEcCtD
Doxylamine—Cardiac disorder—Pravastatin—atherosclerosis	0.000591	0.00416	CcSEcCtD
Doxylamine—Muscle spasms—Simvastatin—atherosclerosis	0.00059	0.00415	CcSEcCtD
Doxylamine—Vertigo—Lovastatin—atherosclerosis	0.000589	0.00415	CcSEcCtD
Doxylamine—Angioedema—Ezetimibe—atherosclerosis	0.000588	0.00414	CcSEcCtD
Doxylamine—Leukopenia—Lovastatin—atherosclerosis	0.000587	0.00413	CcSEcCtD
Doxylamine—Malaise—Ezetimibe—atherosclerosis	0.00058	0.00408	CcSEcCtD
Doxylamine—Clofedanol—HRH1—atherosclerosis	0.000575	0.076	CrCbGaD
Doxylamine—Tremor—Simvastatin—atherosclerosis	0.000575	0.00405	CcSEcCtD
Doxylamine—Insomnia—Rosuvastatin—atherosclerosis	0.000571	0.00402	CcSEcCtD
Doxylamine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000569	0.00401	CcSEcCtD
Doxylamine—Palpitations—Ezetimibe—atherosclerosis	0.000568	0.004	CcSEcCtD
Doxylamine—Erythema—Niacin—atherosclerosis	0.000563	0.00396	CcSEcCtD
Doxylamine—Angioedema—Simvastatin—atherosclerosis	0.00056	0.00395	CcSEcCtD
Doxylamine—Anxiety—Lovastatin—atherosclerosis	0.000556	0.00392	CcSEcCtD
Doxylamine—Malaise—Simvastatin—atherosclerosis	0.000553	0.00389	CcSEcCtD
Doxylamine—Discomfort—Lovastatin—atherosclerosis	0.000551	0.00388	CcSEcCtD
Doxylamine—Vertigo—Simvastatin—atherosclerosis	0.000551	0.00388	CcSEcCtD
Doxylamine—Leukopenia—Simvastatin—atherosclerosis	0.000549	0.00386	CcSEcCtD
Doxylamine—Dry mouth—Lovastatin—atherosclerosis	0.000546	0.00384	CcSEcCtD
Doxylamine—Muscle spasms—Niacin—atherosclerosis	0.000541	0.00381	CcSEcCtD
Doxylamine—Mepyramine—HRH1—atherosclerosis	0.000541	0.0715	CrCbGaD
Doxylamine—Discomfort—Ezetimibe—atherosclerosis	0.000541	0.00381	CcSEcCtD
Doxylamine—Constipation—Rosuvastatin—atherosclerosis	0.00054	0.0038	CcSEcCtD
Doxylamine—Confusional state—Lovastatin—atherosclerosis	0.00054	0.0038	CcSEcCtD
Doxylamine—Dry mouth—Ezetimibe—atherosclerosis	0.000535	0.00377	CcSEcCtD
Doxylamine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000535	0.00377	CcSEcCtD
Doxylamine—Muscle spasms—Pravastatin—atherosclerosis	0.000533	0.00375	CcSEcCtD
Doxylamine—Confusional state—Ezetimibe—atherosclerosis	0.000529	0.00373	CcSEcCtD
Doxylamine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000525	0.0037	CcSEcCtD
Doxylamine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000524	0.00369	CcSEcCtD
Doxylamine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00052	0.00366	CcSEcCtD
Doxylamine—Anxiety—Simvastatin—atherosclerosis	0.00052	0.00366	CcSEcCtD
Doxylamine—Tremor—Pravastatin—atherosclerosis	0.000519	0.00366	CcSEcCtD
Doxylamine—Discomfort—Simvastatin—atherosclerosis	0.000516	0.00363	CcSEcCtD
Doxylamine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000515	0.00362	CcSEcCtD
Doxylamine—Angioedema—Niacin—atherosclerosis	0.000515	0.00362	CcSEcCtD
Doxylamine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000514	0.00362	CcSEcCtD
Doxylamine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000514	0.00362	CcSEcCtD
Doxylamine—Anorexia—Lovastatin—atherosclerosis	0.00051	0.00359	CcSEcCtD
Doxylamine—Angioedema—Pravastatin—atherosclerosis	0.000507	0.00357	CcSEcCtD
Doxylamine—Vertigo—Niacin—atherosclerosis	0.000506	0.00356	CcSEcCtD
Doxylamine—Confusional state—Simvastatin—atherosclerosis	0.000505	0.00355	CcSEcCtD
Doxylamine—Leukopenia—Niacin—atherosclerosis	0.000504	0.00355	CcSEcCtD
Doxylamine—Urticaria—Rosuvastatin—atherosclerosis	0.000502	0.00353	CcSEcCtD
Doxylamine—Tripelennamine—HRH1—atherosclerosis	0.000501	0.0661	CrCbGaD
Doxylamine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000501	0.00352	CcSEcCtD
Doxylamine—Malaise—Pravastatin—atherosclerosis	0.0005	0.00352	CcSEcCtD
Doxylamine—Vertigo—Pravastatin—atherosclerosis	0.000498	0.00351	CcSEcCtD
Doxylamine—Palpitations—Niacin—atherosclerosis	0.000498	0.0035	CcSEcCtD
Doxylamine—Leukopenia—Pravastatin—atherosclerosis	0.000496	0.00349	CcSEcCtD
Doxylamine—Thrombocytopenia—Simvastatin—atherosclerosis	0.00049	0.00345	CcSEcCtD
Doxylamine—Insomnia—Lovastatin—atherosclerosis	0.000484	0.00341	CcSEcCtD
Doxylamine—Anorexia—Simvastatin—atherosclerosis	0.000477	0.00336	CcSEcCtD
Doxylamine—Dyspnoea—Lovastatin—atherosclerosis	0.000477	0.00336	CcSEcCtD
Doxylamine—Insomnia—Ezetimibe—atherosclerosis	0.000475	0.00334	CcSEcCtD
Doxylamine—Anxiety—Pravastatin—atherosclerosis	0.00047	0.00331	CcSEcCtD
Doxylamine—Dry mouth—Niacin—atherosclerosis	0.000469	0.0033	CcSEcCtD
Doxylamine—Dyspnoea—Ezetimibe—atherosclerosis	0.000468	0.00329	CcSEcCtD
Doxylamine—Discomfort—Pravastatin—atherosclerosis	0.000466	0.00328	CcSEcCtD
Doxylamine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000465	0.00328	CcSEcCtD
Doxylamine—Decreased appetite—Lovastatin—atherosclerosis	0.000465	0.00327	CcSEcCtD
Doxylamine—Fatigue—Lovastatin—atherosclerosis	0.000461	0.00325	CcSEcCtD
Doxylamine—Dimetindene—HRH1—atherosclerosis	0.00046	0.0608	CrCbGaD
Doxylamine—Anaphylactic shock—Niacin—atherosclerosis	0.00046	0.00324	CcSEcCtD
Doxylamine—Constipation—Lovastatin—atherosclerosis	0.000458	0.00322	CcSEcCtD
Doxylamine—Confusional state—Pravastatin—atherosclerosis	0.000456	0.00321	CcSEcCtD
Doxylamine—Decreased appetite—Ezetimibe—atherosclerosis	0.000456	0.00321	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000453	0.00319	CcSEcCtD
Doxylamine—Asthenia—Rosuvastatin—atherosclerosis	0.000453	0.00319	CcSEcCtD
Doxylamine—Insomnia—Simvastatin—atherosclerosis	0.000453	0.00319	CcSEcCtD
Doxylamine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000452	0.00319	CcSEcCtD
Doxylamine—Fatigue—Ezetimibe—atherosclerosis	0.000452	0.00319	CcSEcCtD
Doxylamine—Constipation—Ezetimibe—atherosclerosis	0.000449	0.00316	CcSEcCtD
Doxylamine—Tachycardia—Niacin—atherosclerosis	0.000449	0.00316	CcSEcCtD
Doxylamine—Pruritus—Rosuvastatin—atherosclerosis	0.000447	0.00315	CcSEcCtD
Doxylamine—Dyspnoea—Simvastatin—atherosclerosis	0.000446	0.00314	CcSEcCtD
Doxylamine—Hyperhidrosis—Niacin—atherosclerosis	0.000444	0.00313	CcSEcCtD
Doxylamine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000443	0.00312	CcSEcCtD
Doxylamine—Feeling abnormal—Lovastatin—atherosclerosis	0.000441	0.0031	CcSEcCtD
Doxylamine—Anorexia—Niacin—atherosclerosis	0.000438	0.00308	CcSEcCtD
Doxylamine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000437	0.00308	CcSEcCtD
Doxylamine—Decreased appetite—Simvastatin—atherosclerosis	0.000435	0.00306	CcSEcCtD
Doxylamine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000432	0.00305	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000432	0.00304	CcSEcCtD
Doxylamine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000432	0.00304	CcSEcCtD
Doxylamine—Fatigue—Simvastatin—atherosclerosis	0.000432	0.00304	CcSEcCtD
Doxylamine—Anorexia—Pravastatin—atherosclerosis	0.000431	0.00304	CcSEcCtD
Doxylamine—Hypotension—Niacin—atherosclerosis	0.000429	0.00302	CcSEcCtD
Doxylamine—Constipation—Simvastatin—atherosclerosis	0.000428	0.00301	CcSEcCtD
Doxylamine—Urticaria—Lovastatin—atherosclerosis	0.000425	0.00299	CcSEcCtD
Doxylamine—Dizziness—Rosuvastatin—atherosclerosis	0.000418	0.00294	CcSEcCtD
Doxylamine—Urticaria—Ezetimibe—atherosclerosis	0.000417	0.00294	CcSEcCtD
Doxylamine—Insomnia—Niacin—atherosclerosis	0.000416	0.00293	CcSEcCtD
Doxylamine—Feeling abnormal—Simvastatin—atherosclerosis	0.000412	0.0029	CcSEcCtD
Doxylamine—Bromodiphenhydramine—HRH1—atherosclerosis	0.000412	0.0544	CrCbGaD
Doxylamine—Dyspnoea—Niacin—atherosclerosis	0.00041	0.00288	CcSEcCtD
Doxylamine—Insomnia—Pravastatin—atherosclerosis	0.000409	0.00288	CcSEcCtD
Doxylamine—Somnolence—Niacin—atherosclerosis	0.000409	0.00288	CcSEcCtD
Doxylamine—Dyspnoea—Pravastatin—atherosclerosis	0.000403	0.00284	CcSEcCtD
Doxylamine—Decreased appetite—Niacin—atherosclerosis	0.0004	0.00281	CcSEcCtD
Doxylamine—Rash—Rosuvastatin—atherosclerosis	0.000398	0.0028	CcSEcCtD
Doxylamine—Dermatitis—Rosuvastatin—atherosclerosis	0.000398	0.0028	CcSEcCtD
Doxylamine—Urticaria—Simvastatin—atherosclerosis	0.000398	0.0028	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000397	0.00279	CcSEcCtD
Doxylamine—Hypersensitivity—Lovastatin—atherosclerosis	0.000394	0.00278	CcSEcCtD
Doxylamine—Decreased appetite—Pravastatin—atherosclerosis	0.000393	0.00277	CcSEcCtD
Doxylamine—Fatigue—Pravastatin—atherosclerosis	0.00039	0.00275	CcSEcCtD
Doxylamine—Constipation—Pravastatin—atherosclerosis	0.000387	0.00272	CcSEcCtD
Doxylamine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000387	0.00272	CcSEcCtD
Doxylamine—Asthenia—Lovastatin—atherosclerosis	0.000384	0.0027	CcSEcCtD
Doxylamine—Pruritus—Lovastatin—atherosclerosis	0.000379	0.00267	CcSEcCtD
Doxylamine—Asthenia—Ezetimibe—atherosclerosis	0.000377	0.00265	CcSEcCtD
Doxylamine—Nausea—Rosuvastatin—atherosclerosis	0.000375	0.00264	CcSEcCtD
Doxylamine—Feeling abnormal—Pravastatin—atherosclerosis	0.000373	0.00263	CcSEcCtD
Doxylamine—Pruritus—Ezetimibe—atherosclerosis	0.000371	0.00261	CcSEcCtD
Doxylamine—Hypersensitivity—Simvastatin—atherosclerosis	0.000369	0.0026	CcSEcCtD
Doxylamine—Diarrhoea—Lovastatin—atherosclerosis	0.000366	0.00258	CcSEcCtD
Doxylamine—Urticaria—Niacin—atherosclerosis	0.000365	0.00257	CcSEcCtD
Doxylamine—Urticaria—Pravastatin—atherosclerosis	0.000359	0.00253	CcSEcCtD
Doxylamine—Asthenia—Simvastatin—atherosclerosis	0.000359	0.00253	CcSEcCtD
Doxylamine—Diarrhoea—Ezetimibe—atherosclerosis	0.000359	0.00253	CcSEcCtD
Doxylamine—Pruritus—Simvastatin—atherosclerosis	0.000354	0.00249	CcSEcCtD
Doxylamine—Dizziness—Lovastatin—atherosclerosis	0.000354	0.00249	CcSEcCtD
Doxylamine—Dizziness—Ezetimibe—atherosclerosis	0.000347	0.00244	CcSEcCtD
Doxylamine—Diarrhoea—Simvastatin—atherosclerosis	0.000342	0.00241	CcSEcCtD
Doxylamine—Carbinoxamine—HRH1—atherosclerosis	0.000342	0.0452	CrCbGaD
Doxylamine—Vomiting—Lovastatin—atherosclerosis	0.00034	0.0024	CcSEcCtD
Doxylamine—Hypersensitivity—Niacin—atherosclerosis	0.000339	0.00238	CcSEcCtD
Doxylamine—Rash—Lovastatin—atherosclerosis	0.000337	0.00238	CcSEcCtD
Doxylamine—Dermatitis—Lovastatin—atherosclerosis	0.000337	0.00237	CcSEcCtD
Doxylamine—Vomiting—Ezetimibe—atherosclerosis	0.000334	0.00235	CcSEcCtD
Doxylamine—Hypersensitivity—Pravastatin—atherosclerosis	0.000333	0.00235	CcSEcCtD
Doxylamine—Dizziness—Simvastatin—atherosclerosis	0.000331	0.00233	CcSEcCtD
Doxylamine—Rash—Ezetimibe—atherosclerosis	0.000331	0.00233	CcSEcCtD
Doxylamine—Dermatitis—Ezetimibe—atherosclerosis	0.000331	0.00233	CcSEcCtD
Doxylamine—Asthenia—Niacin—atherosclerosis	0.00033	0.00232	CcSEcCtD
Doxylamine—Pruritus—Niacin—atherosclerosis	0.000325	0.00229	CcSEcCtD
Doxylamine—Asthenia—Pravastatin—atherosclerosis	0.000325	0.00229	CcSEcCtD
Doxylamine—Pruritus—Pravastatin—atherosclerosis	0.00032	0.00225	CcSEcCtD
Doxylamine—Vomiting—Simvastatin—atherosclerosis	0.000318	0.00224	CcSEcCtD
Doxylamine—Nausea—Lovastatin—atherosclerosis	0.000318	0.00224	CcSEcCtD
Doxylamine—Rash—Simvastatin—atherosclerosis	0.000316	0.00222	CcSEcCtD
Doxylamine—Dermatitis—Simvastatin—atherosclerosis	0.000315	0.00222	CcSEcCtD
Doxylamine—Diarrhoea—Niacin—atherosclerosis	0.000314	0.00221	CcSEcCtD
Doxylamine—Nausea—Ezetimibe—atherosclerosis	0.000312	0.00219	CcSEcCtD
Doxylamine—Diarrhoea—Pravastatin—atherosclerosis	0.00031	0.00218	CcSEcCtD
Doxylamine—Dizziness—Niacin—atherosclerosis	0.000304	0.00214	CcSEcCtD
Doxylamine—Dizziness—Pravastatin—atherosclerosis	0.000299	0.00211	CcSEcCtD
Doxylamine—Nausea—Simvastatin—atherosclerosis	0.000297	0.00209	CcSEcCtD
Doxylamine—Brompheniramine—HRH1—atherosclerosis	0.000296	0.0392	CrCbGaD
Doxylamine—Vomiting—Niacin—atherosclerosis	0.000292	0.00206	CcSEcCtD
Doxylamine—Chlorphenamine—HRH1—atherosclerosis	0.000291	0.0384	CrCbGaD
Doxylamine—Rash—Niacin—atherosclerosis	0.00029	0.00204	CcSEcCtD
Doxylamine—Dermatitis—Niacin—atherosclerosis	0.00029	0.00204	CcSEcCtD
Doxylamine—Vomiting—Pravastatin—atherosclerosis	0.000288	0.00203	CcSEcCtD
Doxylamine—Rash—Pravastatin—atherosclerosis	0.000285	0.00201	CcSEcCtD
Doxylamine—Dermatitis—Pravastatin—atherosclerosis	0.000285	0.00201	CcSEcCtD
Doxylamine—Nausea—Niacin—atherosclerosis	0.000273	0.00192	CcSEcCtD
Doxylamine—Nausea—Pravastatin—atherosclerosis	0.000269	0.00189	CcSEcCtD
Doxylamine—Toremifene—ESR1—atherosclerosis	0.00025	0.033	CrCbGaD
Doxylamine—Diphenhydramine—HRH1—atherosclerosis	0.000197	0.0261	CrCbGaD
Doxylamine—Doxepin—HRH1—atherosclerosis	0.000192	0.0253	CrCbGaD
Doxylamine—Orphenadrine—HRH1—atherosclerosis	0.000187	0.0247	CrCbGaD
Doxylamine—Promazine—HRH1—atherosclerosis	0.00017	0.0225	CrCbGaD
Doxylamine—Tamoxifen—ESR2—atherosclerosis	0.000162	0.0214	CrCbGaD
Doxylamine—Imipramine—HRH1—atherosclerosis	0.000149	0.0197	CrCbGaD
Doxylamine—Amitriptyline—HRH1—atherosclerosis	0.000148	0.0196	CrCbGaD
Doxylamine—Tamoxifen—ESR1—atherosclerosis	9.97e-05	0.0132	CrCbGaD
Doxylamine—Amitriptyline—ALB—atherosclerosis	3.42e-05	0.00452	CrCbGaD
Doxylamine—CHRM1—Signaling by GPCR—HRH1—atherosclerosis	1.2e-05	0.00353	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	1.18e-05	0.00346	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	1.18e-05	0.00345	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	1.17e-05	0.00344	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	1.17e-05	0.00343	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CCL3—atherosclerosis	1.16e-05	0.00341	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CCL3—atherosclerosis	1.16e-05	0.0034	CbGpPWpGaD
Doxylamine—HRH1—G alpha (q) signalling events—F2—atherosclerosis	1.15e-05	0.00338	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—LEP—atherosclerosis	1.15e-05	0.00337	CbGpPWpGaD
Doxylamine—CHRM1—G alpha (q) signalling events—F2—atherosclerosis	1.15e-05	0.00337	CbGpPWpGaD
Doxylamine—HRH1—IL-4 Signaling Pathway—AKT1—atherosclerosis	1.14e-05	0.00334	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	1.11e-05	0.00327	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	1.11e-05	0.00326	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—NOS2—atherosclerosis	1.07e-05	0.00314	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CCR2—atherosclerosis	1.05e-05	0.00308	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—EDNRA—atherosclerosis	1.05e-05	0.00308	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—EDNRA—atherosclerosis	1.05e-05	0.00307	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CCR2—atherosclerosis	1.05e-05	0.00307	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	1.03e-05	0.00302	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	1.03e-05	0.00301	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—GHRL—atherosclerosis	1.02e-05	0.00301	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—GHRL—atherosclerosis	1.02e-05	0.003	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—PPARG—atherosclerosis	1e-05	0.00294	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	9.94e-06	0.00292	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	9.91e-06	0.00291	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	9.86e-06	0.0029	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	9.83e-06	0.00289	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—SERPINE1—atherosclerosis	9.01e-06	0.00265	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—KNG1—atherosclerosis	8.98e-06	0.00264	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—KNG1—atherosclerosis	8.95e-06	0.00263	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—AGTR1—atherosclerosis	8.93e-06	0.00262	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—AGTR1—atherosclerosis	8.9e-06	0.00261	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL4—atherosclerosis	8.72e-06	0.00256	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL4—atherosclerosis	8.69e-06	0.00255	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—UTS2—atherosclerosis	8.56e-06	0.00251	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—UTS2—atherosclerosis	8.53e-06	0.00251	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	8.25e-06	0.00242	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	8.22e-06	0.00242	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CASR—atherosclerosis	8.21e-06	0.00241	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CASR—atherosclerosis	8.18e-06	0.0024	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—UTS2—atherosclerosis	7.77e-06	0.00228	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—UTS2—atherosclerosis	7.75e-06	0.00228	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CNR2—atherosclerosis	7.63e-06	0.00224	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	7.62e-06	0.00224	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CNR2—atherosclerosis	7.61e-06	0.00223	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	7.6e-06	0.00223	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—EDN1—atherosclerosis	7.57e-06	0.00222	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—EDN1—atherosclerosis	7.54e-06	0.00222	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CCL5—atherosclerosis	7.51e-06	0.00221	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CCL5—atherosclerosis	7.49e-06	0.0022	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CX3CR1—atherosclerosis	7.45e-06	0.00219	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CASR—atherosclerosis	7.45e-06	0.00219	CbGpPWpGaD
Doxylamine—CHRM1—Regulation of Actin Cytoskeleton—MAPK3—atherosclerosis	7.45e-06	0.00219	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CX3CR1—atherosclerosis	7.43e-06	0.00218	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CASR—atherosclerosis	7.43e-06	0.00218	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CX3CL1—atherosclerosis	7.31e-06	0.00215	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CX3CL1—atherosclerosis	7.29e-06	0.00214	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HRH1—atherosclerosis	7.1e-06	0.00209	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CNR2—atherosclerosis	6.93e-06	0.00204	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CNR2—atherosclerosis	6.91e-06	0.00203	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	6.79e-06	0.002	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	6.77e-06	0.00199	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—MAPK8—atherosclerosis	6.71e-06	0.00197	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—AGT—atherosclerosis	6.28e-06	0.00185	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—AGT—atherosclerosis	6.26e-06	0.00184	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL3—atherosclerosis	5.96e-06	0.00175	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL3—atherosclerosis	5.94e-06	0.00174	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CCR2—atherosclerosis	5.93e-06	0.00174	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—EDNRA—atherosclerosis	5.93e-06	0.00174	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—EDNRA—atherosclerosis	5.91e-06	0.00174	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CCR2—atherosclerosis	5.91e-06	0.00174	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—F2—atherosclerosis	5.8e-06	0.00171	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—F2—atherosclerosis	5.79e-06	0.0017	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GHRL—atherosclerosis	5.78e-06	0.0017	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GHRL—atherosclerosis	5.76e-06	0.00169	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOA4—atherosclerosis	5.59e-06	0.00164	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOA4—atherosclerosis	5.57e-06	0.00164	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	5.57e-06	0.00164	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	5.56e-06	0.00163	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EDNRA—atherosclerosis	5.39e-06	0.00158	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCR2—atherosclerosis	5.39e-06	0.00158	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	5.37e-06	0.00158	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EDNRA—atherosclerosis	5.37e-06	0.00158	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCR2—atherosclerosis	5.37e-06	0.00158	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	5.35e-06	0.00157	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GHRL—atherosclerosis	5.25e-06	0.00154	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GHRL—atherosclerosis	5.23e-06	0.00154	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CCL2—atherosclerosis	5.17e-06	0.00152	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CCL2—atherosclerosis	5.16e-06	0.00151	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL4—atherosclerosis	5.15e-06	0.00151	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL4—atherosclerosis	5.14e-06	0.00151	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—KNG1—atherosclerosis	5.08e-06	0.00149	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—KNG1—atherosclerosis	5.06e-06	0.00149	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AGTR1—atherosclerosis	5.05e-06	0.00148	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AGTR1—atherosclerosis	5.03e-06	0.00148	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOA2—atherosclerosis	4.81e-06	0.00141	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOA2—atherosclerosis	4.8e-06	0.00141	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—KNG1—atherosclerosis	4.61e-06	0.00135	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—KNG1—atherosclerosis	4.59e-06	0.00135	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—UTS2—atherosclerosis	4.59e-06	0.00135	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AGTR1—atherosclerosis	4.58e-06	0.00135	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—UTS2—atherosclerosis	4.58e-06	0.00134	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AGTR1—atherosclerosis	4.57e-06	0.00134	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CX3CR1—atherosclerosis	4.4e-06	0.00129	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASR—atherosclerosis	4.4e-06	0.00129	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CX3CR1—atherosclerosis	4.39e-06	0.00129	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASR—atherosclerosis	4.39e-06	0.00129	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CX3CL1—atherosclerosis	4.32e-06	0.00127	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CX3CL1—atherosclerosis	4.3e-06	0.00126	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—IL6—atherosclerosis	4.29e-06	0.00126	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—EDN1—atherosclerosis	4.28e-06	0.00126	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—EDN1—atherosclerosis	4.26e-06	0.00125	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CCL5—atherosclerosis	4.24e-06	0.00125	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CCL5—atherosclerosis	4.23e-06	0.00124	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CNR2—atherosclerosis	4.09e-06	0.0012	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CXCL8—atherosclerosis	4.09e-06	0.0012	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MMP3—atherosclerosis	4.08e-06	0.0012	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CNR2—atherosclerosis	4.08e-06	0.0012	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CXCL8—atherosclerosis	4.08e-06	0.0012	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	4.07e-06	0.0012	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MMP3—atherosclerosis	4.07e-06	0.0012	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	4.06e-06	0.00119	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PRKCG—atherosclerosis	4.03e-06	0.00119	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCG—atherosclerosis	4.02e-06	0.00118	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EDN1—atherosclerosis	3.88e-06	0.00114	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EDN1—atherosclerosis	3.87e-06	0.00114	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL5—atherosclerosis	3.85e-06	0.00113	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL5—atherosclerosis	3.84e-06	0.00113	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCG—atherosclerosis	3.66e-06	0.00108	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCG—atherosclerosis	3.65e-06	0.00107	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VWF—atherosclerosis	3.65e-06	0.00107	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VWF—atherosclerosis	3.64e-06	0.00107	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOC3—atherosclerosis	3.63e-06	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOC3—atherosclerosis	3.61e-06	0.00106	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LDLR—atherosclerosis	3.6e-06	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LDLR—atherosclerosis	3.59e-06	0.00106	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AGT—atherosclerosis	3.55e-06	0.00104	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AGT—atherosclerosis	3.54e-06	0.00104	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL3—atherosclerosis	3.52e-06	0.00103	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL3—atherosclerosis	3.51e-06	0.00103	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NCF1—atherosclerosis	3.37e-06	0.00099	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NCF1—atherosclerosis	3.36e-06	0.000987	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—F2—atherosclerosis	3.28e-06	0.000964	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—F2—atherosclerosis	3.27e-06	0.000961	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AGT—atherosclerosis	3.22e-06	0.000947	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AGT—atherosclerosis	3.21e-06	0.000944	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EDNRA—atherosclerosis	3.18e-06	0.000935	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCR2—atherosclerosis	3.18e-06	0.000935	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCR2—atherosclerosis	3.17e-06	0.000932	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EDNRA—atherosclerosis	3.17e-06	0.000932	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CYBA—atherosclerosis	3.17e-06	0.000931	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CYBA—atherosclerosis	3.16e-06	0.000928	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—atherosclerosis	3.14e-06	0.000922	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—atherosclerosis	3.13e-06	0.000919	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PARP1—atherosclerosis	3.1e-06	0.000911	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PLAT—atherosclerosis	3.1e-06	0.000911	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GHRL—atherosclerosis	3.1e-06	0.000911	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PLAT—atherosclerosis	3.09e-06	0.000908	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GHRL—atherosclerosis	3.09e-06	0.000908	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PARP1—atherosclerosis	3.09e-06	0.000908	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—F2—atherosclerosis	2.98e-06	0.000875	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—F2—atherosclerosis	2.97e-06	0.000872	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—atherosclerosis	2.85e-06	0.000837	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—atherosclerosis	2.84e-06	0.000835	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KNG1—atherosclerosis	2.72e-06	0.0008	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KNG1—atherosclerosis	2.71e-06	0.000797	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AGTR1—atherosclerosis	2.71e-06	0.000795	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AGTR1—atherosclerosis	2.7e-06	0.000792	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL2—atherosclerosis	2.66e-06	0.00078	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL2—atherosclerosis	2.65e-06	0.000777	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PLG—atherosclerosis	2.64e-06	0.000775	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PLG—atherosclerosis	2.63e-06	0.000772	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SOCS3—atherosclerosis	2.5e-06	0.000734	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SOCS3—atherosclerosis	2.49e-06	0.000731	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP3—atherosclerosis	2.41e-06	0.000709	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP3—atherosclerosis	2.4e-06	0.000706	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF2—atherosclerosis	2.4e-06	0.000705	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF2—atherosclerosis	2.39e-06	0.000703	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOB—atherosclerosis	2.33e-06	0.000685	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOB—atherosclerosis	2.32e-06	0.000683	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CXCL8—atherosclerosis	2.31e-06	0.000679	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CXCL8—atherosclerosis	2.3e-06	0.000677	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EDN1—atherosclerosis	2.29e-06	0.000674	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EDN1—atherosclerosis	2.29e-06	0.000672	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL5—atherosclerosis	2.28e-06	0.000669	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL5—atherosclerosis	2.27e-06	0.000667	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LPL—atherosclerosis	2.23e-06	0.000654	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LPL—atherosclerosis	2.22e-06	0.000652	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCG—atherosclerosis	2.16e-06	0.000636	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	2.16e-06	0.000634	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SPP1—atherosclerosis	2.11e-06	0.000619	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SPP1—atherosclerosis	2.1e-06	0.000617	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCL8—atherosclerosis	2.1e-06	0.000617	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	2.09e-06	0.000615	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFB—atherosclerosis	1.95e-06	0.000573	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	1.94e-06	0.000571	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AGT—atherosclerosis	1.9e-06	0.000559	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AGT—atherosclerosis	1.9e-06	0.000558	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LEP—atherosclerosis	1.87e-06	0.000548	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOE—atherosclerosis	1.87e-06	0.000548	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOE—atherosclerosis	1.86e-06	0.000546	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LEP—atherosclerosis	1.86e-06	0.000546	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CAV1—atherosclerosis	1.85e-06	0.000543	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOA1—atherosclerosis	1.84e-06	0.000542	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CAV1—atherosclerosis	1.84e-06	0.000541	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOA1—atherosclerosis	1.84e-06	0.00054	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ESR1—atherosclerosis	1.78e-06	0.000523	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ESR1—atherosclerosis	1.78e-06	0.000522	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—F2—atherosclerosis	1.76e-06	0.000517	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—F2—atherosclerosis	1.75e-06	0.000515	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	1.68e-06	0.000495	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.68e-06	0.000493	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	1.61e-06	0.000474	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	1.61e-06	0.000472	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—INS—atherosclerosis	1.59e-06	0.000468	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—INS—atherosclerosis	1.59e-06	0.000467	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL2—atherosclerosis	1.57e-06	0.000461	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL2—atherosclerosis	1.56e-06	0.000459	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF1—atherosclerosis	1.54e-06	0.000453	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF1—atherosclerosis	1.54e-06	0.000451	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	1.46e-06	0.00043	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	1.46e-06	0.000429	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOS3—atherosclerosis	1.4e-06	0.000411	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	1.39e-06	0.000409	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	1.24e-06	0.000364	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	1.24e-06	0.000363	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	1.2e-06	0.000352	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	1.19e-06	0.000351	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6—atherosclerosis	1.18e-06	0.000346	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	1.18e-06	0.000345	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP9—atherosclerosis	1.12e-06	0.000329	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	1.12e-06	0.000328	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	1.11e-06	0.000326	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	1.11e-06	0.000325	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	1.09e-06	0.00032	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	1.09e-06	0.00032	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	1.09e-06	0.000319	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	1.08e-06	0.000319	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	1.01e-06	0.000296	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	1e-06	0.000295	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—atherosclerosis	9.97e-07	0.000293	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	9.94e-07	0.000292	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	9.53e-07	0.00028	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	9.5e-07	0.000279	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	9.24e-07	0.000272	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	9.21e-07	0.000271	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6—atherosclerosis	6.97e-07	0.000205	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6—atherosclerosis	6.94e-07	0.000204	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—atherosclerosis	6.43e-07	0.000189	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	6.41e-07	0.000188	CbGpPWpGaD
